Video: Outsmarting Cancer with Computational Precision Oncology

In this video, Dr. Peták shares the groundbreaking results of a newly published five-year follow-up study in NPJ Precision Oncology. The study demonstrates that lung cancer patients receiving targeted therapies, chosen not only based on specific biomarkers but also optimized through a computational model called Digital Drug Assignment; achieved a 33% five-year survival rate, compared to just 6% in patients receiving non-optimized therapies.Dr. Peták highlights the transformative potential of combining precision medicine with computational tools to match the right therapy to the molecular profile of each patient. This marks a hopeful turning point in the fight against cancer, showcasing how we can begin to outsmart even the most complex diseases by embracing advanced computational tools.